Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CSK | P41240 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054302 | 0.89 | AURKA (0.57) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL3431187 | 0.88 | AURKA (0.81) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL3429837 | 0.88 | AURKA (0.81) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL5043450 | 0.87 | AURKA (0.76) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL2052923 | 0.87 | PDGFRB (0.65) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL6027924 | 0.87 | AURKA (0.75) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL2049861 | 0.84 | AURKA (0.67) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL2049238 | 0.83 | AURKA (0.64) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL2048275 | 0.82 | AURKA (0.60) | AURKAAURKBPDGFRBFLT4FLT3 | |
| SCHEMBL5048641 | 0.82 | AURKA (0.87) | AURKAAURKBPDGFRBFLT4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | claimed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | AURKA 466/4885AURKB 369/4885PDGFRB 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.